These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 19390331)
1. Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV/HCV-coinfected individuals treated with antiretroviral therapy. Morsica G; Bagaglio S; Uberti-Foppa C; Galli L; Lazzarin A J Acquir Immune Defic Syndr; 2009 May; 51(1):106-8. PubMed ID: 19390331 [No Abstract] [Full Text] [Related]
2. Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patients. Aparicio E; Franco S; Parera M; Andrés C; Tural C; Clotet B; Martínez MA J Virol; 2011 Jun; 85(12):5961-9. PubMed ID: 21471227 [TBL] [Abstract][Full Text] [Related]
3. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates. López-Labrador FX; Moya A; Gonzàlez-Candelas F Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527 [TBL] [Abstract][Full Text] [Related]
4. Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients. Trimoulet P; Belzunce C; Faure M; Wittkop L; Reigadas S; Dupon M; Ragnaud JM; Fleury H; Neau D HIV Med; 2011 Sep; 12(8):506-9. PubMed ID: 21410862 [TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV. Silva T; Cortes Martins H; Coutinho R; Leitão E; Silva R; Pádua E J Med Virol; 2015 Sep; 87(9):1549-57. PubMed ID: 25940586 [TBL] [Abstract][Full Text] [Related]
6. Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naive individuals infected with hepatitis C virus. Bagaglio S; Messina E; Uberti-Foppa C; Merli M; Torre LD; Lazzarin A; Hasson H; Morsica G J Antimicrob Chemother; 2013 Jun; 68(6):1448-50. PubMed ID: 23390206 [No Abstract] [Full Text] [Related]
7. Natural presence of NS3 protease R155K hepatitis C virus variants with decreased sensitivity to protease inhibitors. Colson P; Purgus R; Borentain P; Gérolami R J Clin Virol; 2012 Feb; 53(2):178-80. PubMed ID: 22079973 [No Abstract] [Full Text] [Related]
8. The Investigation of Drug Resistance Substitutions in NS3 Protease Sequence of Hepatitis C Virus from Non-Responder Patients. Nejabat N; Hosseini SY; Sarvari J; Gorzin AA; Fattahi MR; Rasoolian M Asian Pac J Cancer Prev; 2019 Aug; 20(8):2311-2317. PubMed ID: 31450900 [TBL] [Abstract][Full Text] [Related]
9. Hepatitis C virus NS3/4A quasispecies diversity in acute hepatitis C infection in HIV-1 co-infected patients. Nevot M; Boesecke C; Parera M; Andrés C; Franco S; Revollo B; Ingiliz P; Tural C; Clotet B; Rockstroh JK; Martinez MA; J Viral Hepat; 2014 Jun; 21(6):e19-28. PubMed ID: 24674023 [TBL] [Abstract][Full Text] [Related]
10. Temporal dynamics of a predominant protease inhibitor-resistance mutation in a treatment-naive, hepatitis C virus-infected individual. Kim AY; Timm J; Nolan BE; Reyor LL; Kane K; Berical AC; Zachary KC; Lauer GM; Kuntzen T; Allen TM J Infect Dis; 2009 Mar; 199(5):737-41. PubMed ID: 19199553 [TBL] [Abstract][Full Text] [Related]
11. New protease inhibitors for HCV--help is on the way. Fusco DN; Chung RT J Hepatol; 2011 Jun; 54(6):1087-9. PubMed ID: 21232563 [No Abstract] [Full Text] [Related]
12. Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients. Treviño A; de Mendoza C; Parra P; Rodríguez C; Madejón A; Plaza Z; del Romero J; Poveda E; Soriano V Antivir Ther; 2011; 16(3):413-6. PubMed ID: 21555824 [TBL] [Abstract][Full Text] [Related]
13. Dynamic change in the NS3 protease domain in HIV/HCV-coinfected patients naïve to anti-HCV protease inhibitors. Bagaglio S; Messina E; Hasson H; Merli M; Andolina A; Lazzarin A; Uberti-Foppa C; Morsica G New Microbiol; 2017 Jan; 40(1):53-55. PubMed ID: 28072886 [TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus NS3 mutations in haemophiliacs. Lin MV; Charlton AN; Rouster SD; Zamor PJ; Sherman KE Haemophilia; 2014 Sep; 20(5):659-65. PubMed ID: 24697920 [TBL] [Abstract][Full Text] [Related]
15. Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection. Lisboa-Neto G; Noble CF; Pinho JR; Malta FM; Gomes-Gouvêa MS; Alvarado-Mora MV; da Silva MH; Leite AG; Piccoli LZ; Rodrigues FK; Carrilho FJ; Mendes-Correa MC Antivir Ther; 2015; 20(3):281-7. PubMed ID: 25279715 [TBL] [Abstract][Full Text] [Related]
16. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy. Vicenti I; Rosi A; Saladini F; Meini G; Pippi F; Rossetti B; Sidella L; Di Giambenedetto S; Almi P; De Luca A; Caudai C; Zazzi M J Antimicrob Chemother; 2012 Apr; 67(4):984-7. PubMed ID: 22258932 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors. Boloor A; Hanway D; Joshi M; Winn DT; Mendez G; Walls M; Wei P; Qian F; Zhang X; Zhang Y; Hepperle ME; Li X; Campbell DA; Betancort JM Bioorg Med Chem Lett; 2009 Oct; 19(19):5708-11. PubMed ID: 19713109 [TBL] [Abstract][Full Text] [Related]
18. Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors. Franco S; Bellido R; Aparicio E; Cañete N; García-Retortillo M; Solà R; Tural C; Clotet B; Paredes R; Martínez MA J Viral Hepat; 2011 Oct; 18(10):e578-82. PubMed ID: 21914079 [TBL] [Abstract][Full Text] [Related]
19. HCV NS3/4A protein activates HIV-1 transcription from its long terminal repeat. Wu X; Ishaq M; Hu J; Guo D Virus Res; 2008 Jul; 135(1):155-60. PubMed ID: 18433908 [TBL] [Abstract][Full Text] [Related]
20. Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning. Cuypers L; Libin P; Schrooten Y; Theys K; Di Maio VC; Cento V; Lunar MM; Nevens F; Poljak M; Ceccherini-Silberstein F; Nowé A; Van Laethem K; Vandamme AM Infect Genet Evol; 2017 Sep; 53():15-23. PubMed ID: 28499845 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]